EnBio Holdings Inc
EnBio Holdings Inc provides industrial services, primarily in the environmental services and equipment sector, generating revenue through the provision of specialized industrial services.
Business. EnBio Holdings Inc (6092.T) is an environmental services and equipment company headquartered in Japan and listed on the Tokyo Stock Exchange. The firm operates within the Industrial & Commercial Services sector, focusing on industrial services and product sales. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
EnBio Holdings Inc (6092.T) is an environmental services and equipment company headquartered in Japan and listed on the Tokyo Stock Exchange. The firm operates within the Industrial & Commercial Services sector, focusing on industrial services and product sales. Specific details regarding operating segments and geographic revenue mix are not available.
EnBio Holdings Inc maintains a capital structure with a debt-to-equity ratio of 1.01, indicating a balanced mix of debt and equity financing. The company's liquidity position is characterized by a current ratio of 1.99, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
In terms of profitability, EnBio reports a return on equity (ROE) of 4.28% and a return on assets (ROA) of 1.88%. These figures are below the typical thresholds for strong performance in the industrial services sector, indicating that the company is generating modest returns relative to its equity and asset base.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if the segment faces headwinds.
Looking ahead, EnBio's growth trajectory is modest, with no specific revenue growth projections provided in the available data. The company's capital expenditures for the period were -1,079,075,000 JPY, indicating a reduction in investment in long-term assets, which may affect future growth potential.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in maintaining liquidity without external financing. No dilution sources are identified in the available data, and the dilution risk is assessed as low.
Recent financial filings and transcripts do not provide additional insights into the company's strategic direction or operational performance beyond what is disclosed in the financial snapshot. The company's last actual EPS was 55.90 JPY, and its last actual revenue was 10,668,080,000 JPY, according to analyst estimates.
- EnBio Holdings Inc has a balanced capital structure with a debt-to-equity ratio of 1.01.
- The company's return on equity and return on assets are below typical thresholds for strong performance in the industrial services sector.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's capital expenditures were negative, indicating a reduction in investment in long-term assets.
- EnBio faces medium liquidity risk due to a negative net cash position after subtracting total debt.
- The company's dilution risk is assessed as low, with no identified dilution sources.
Bull / Bear case
Generated · model-assistedRevenue grew 11.4% year-over-year to 10.7 billion JPY, demonstrating strong top-line expansion momentum.
Cash conversion ratio of 4.71 is best-in-class, far surpassing the 0.95 cohort median.
Revenue CAGR of 11.8% over four years highlights consistent long-term growth trajectory.
High credit risk flag indicates significant potential for financial distress or default issues.
Debt-to-equity ratio of 1.01 is more than double the 0.43 cohort median, increasing leverage risk.
Long-term debt increased to 10.1 billion JPY, rising alongside deteriorating cash flow generation.
In focus — financials by report
Revenue ¥3.42B, +53,2% YoY; Operating income −836,6% YoY.
- ▍Revenue ¥3.42B, +53,2% YoY
- ▍Operating income −836,6% YoY
- ▍Net income −506,2% YoY
- ▍Net margin -17.8%
Revenue ¥3.25B, +9,5% YoY; Operating income +42,9% YoY.
- ▍Revenue ¥3.25B, +9,5% YoY
- ▍Operating income +42,9% YoY
- ▍Net income +735,3% YoY
- ▍Net margin 16.5%
Revenue ¥2.44B, −18,7% YoY; Operating income −70,4% YoY.
- ▍Revenue ¥2.44B, −18,7% YoY
- ▍Operating income −70,4% YoY
- ▍Net income −97,4% YoY
- ▍Net margin 0.4%
Revenue ¥2.48B, −4,4% YoY; Operating income −98,8% YoY.
- ▍Revenue ¥2.48B, −4,4% YoY
- ▍Operating income −98,8% YoY
- ▍Net income −131,1% YoY
- ▍Net margin -4.6%
Revenue ¥2.23B; Operating income ¥62.5M.
- ▍Revenue ¥2.23B
- ▍Operating income ¥62.5M
- ▍Net margin 6.7%
Revenue ¥2.96B; Operating income ¥377.3M.
- ▍Revenue ¥2.96B
- ▍Operating income ¥377.3M
- ▍Net margin 2.2%
Revenue ¥3.00B; Operating income ¥395.4M.
- ▍Revenue ¥3.00B
- ▍Operating income ¥395.4M
- ▍Net margin 11.7%
Revenue ¥2.59B; Operating income ¥347.8M.
- ▍Revenue ¥2.59B
- ▍Operating income ¥347.8M
- ▍Net margin 14.0%
Revenue ¥10.67B, +11,4% YoY; Operating income +3,2% YoY.
- ▍Revenue ¥10.67B, +11,4% YoY
- ▍Operating income +3,2% YoY
- ▍Net income −36,1% YoY
- ▍Free cash flow −1 427,9% YoY
- ▍Net margin 4.2%
Revenue ¥9.58B, +17,9% YoY; Operating income −34,8% YoY.
- ▍Revenue ¥9.58B, +17,9% YoY
- ▍Operating income −34,8% YoY
- ▍Net income −12,7% YoY
- ▍Free cash flow +305,8% YoY
- ▍Net margin 7.4%
Revenue ¥8.12B, −9,7% YoY; Operating income +10,0% YoY.
- ▍Revenue ¥8.12B, −9,7% YoY
- ▍Operating income +10,0% YoY
- ▍Net income +24,2% YoY
- ▍Free cash flow +80,7% YoY
- ▍Net margin 10.0%
Revenue ¥8.99B, +31,4% YoY; Operating income +125,8% YoY.
- ▍Revenue ¥8.99B, +31,4% YoY
- ▍Operating income +125,8% YoY
- ▍Net income +115,1% YoY
- ▍Free cash flow +88,7% YoY
- ▍Net margin 7.3%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- EnBio Holdings Inc Market data — financials · 2026-05-27
- EnBio Holdings Inc Market data — analyst estimates · 2026-05-27